loading page

Impaired endothelial function irrespective of systemic inflammation or atherosclerosis in mastoscytosis
  • +10
  • Nida Oztop,
  • Pelin Karaca Özer,
  • semra demir,
  • Sengul Beyaz,
  • Tarık Tiryaki,
  • Gulkan Ozkan,
  • Mehmet Aydogan,
  • Melike Buğra,
  • Bahattin Çolakoğlu,
  • Suna Büyüköztürk,
  • Meliha Nalcaci,
  • Akif Yavuz,
  • Aslı Gelincik
Nida Oztop
Istanbul University Istanbul Faculty of Medicine
Author Profile
Pelin Karaca Özer
Istanbul University Istanbul Faculty of Medicine
Author Profile
semra demir
Istanbul University Istanbul Faculty of Medicine
Author Profile
Sengul Beyaz
Istanbul University Istanbul Faculty of Medicine
Author Profile
Tarık Tiryaki
Istanbul University Istanbul Faculty of Medicine
Author Profile
Gulkan Ozkan
Ministry of Health Istanbul Şişli Hamidiye Etfal Training and Research Hospital
Author Profile
Mehmet Aydogan
Istanbul University Istanbul Faculty of Medicine
Author Profile
Melike Buğra
Istanbul University Istanbul Faculty of Medicine
Author Profile
Bahattin Çolakoğlu
Istanbul Faculty of Medicine
Author Profile
Suna Büyüköztürk
Istanbul University, Istanbul Faculty of Medicine
Author Profile
Meliha Nalcaci
Istanbul University Istanbul Faculty of Medicine
Author Profile
Akif Yavuz
Istanbul University Istanbul Faculty of Medicine
Author Profile
Aslı Gelincik
Istanbul University Istanbul Faculty of Medicine
Author Profile

Abstract

Background: Knowledge on endothelial dysfunction and its relation to atherosclerosis in mastocytosis is limited. Aim: To investigate the endothelial function in mastocytosis by flow mediated dilatation (FMD) and biomarkers related to vascular endothelia, the presence of subclinical atherosclerosis by carotid intima media thickness (CIMT). Method: Forty-nine patients with mastocytosis and 25 healthy controls (HCs) were included. FMD and CIMT during transthoracic echocardiography, biomarkers including endocan, endothelin-1 (ET-1), vascular endothelial growth factor (VEGF) were measured in sera of participants. Tumor necrosis factor-alpha (TNF-α), interleukine-6 (IL-6) and high sensitive c-reactive protein (hsCRP) were determined as inflammatory biomarkers. Result: The mean FMD% was lower in the patients than HCs (11.26±5.85% vs 17.84±5.27% p<0.001) and was the lowest in the advSM and SSM group among the patients (p=0.03). The median value of VEGF was significantly higher in patients than HCs. [73.30 pg/mL; min-max (32.46-295.29) pg/mL vs (46.64 pg/mL; min-max 11.09-99.86 pg/mL; p:0.001] and it was the highest in the advSM and SSM group (p:0.01). FMD was inversely correlated with endocan (r:-.390, p:0.006), ET-1 (r:-.363, p:0.01) and VEGF (r:-.402, p:0.004) but there were no correlations between FMD and TNF-α, IL-6, and hsCRP. No differences in CIMT values between patients and HCs and no correlation between CIMT and the biomarkers were observed. Conclusion: Endothelial dysfunction in mastocytosis becomes evident with decreased FMD and elevated serum VEGF, in the absence of atherosclerosis or systemic inflammation and is related to disease severity. Keywords: CIMT, Endocan, Endothelial function, Endothelin-1, FMD, VEGF